ClinicalTrials.gg

Program

prasinezumab

Also written as “Prasinezumab”, “RO7046015” and “PRX002”.

Its studies are mostly in Parkinson Disease, led by 2 companies.

Furthest: phase 3, since Sep 12, 20255 company-led studies, 3 open or runningNext primary completion: Jun 30, 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche33 open or runningphase 3since Sep 12, 2025Mar 29, 2017Jun 30, 2029phase 3 · NCT07174310
Prothena Biosciences20 open or runningphase 1since Mar 14, 2014Mar 14, 2014none ahead
  • Named in Hoffmann-La Roche’s own pipeline as RG7935 prasinezumab, phase 3, as of Oct 22, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 14, 2014First study: phase 1 study in Parkinson DiseaseNew to Prothena BiosciencesProthena Biosciences · NCT02095171 · 40 enrolled · United States
  2. Jun 4, 2014Phase 1 study in Parkinson DiseaseProthena Biosciences · NCT02157714 · 64 enrolled · United States
  3. Mar 29, 2017Hoffmann-La Roche's first study: phase 2 study in Parkinson DiseaseNew to Hoffmann-La RocheHoffmann-La Roche · NCT03100149 · 316 enrolled · United States, Austria, France and more
  4. Feb 26, 2021Phase 2 study in Parkinson DiseaseHoffmann-La Roche · NCT04777331 · 586 enrolled · United States, Austria, Canada and more
  5. Sep 12, 2025Phase 3 study in Parkinson DiseaseHoffmann-La Roche · NCT07174310 · 900 planned · United States, Australia, Austria and more

Ahead

  1. Jun 30, 2029Primary completion: phase 3 study in Parkinson DiseaseHoffmann-La Roche · NCT07174310

TargetBeta

SNCA →read by rule
“Alpha-synuclein binding agent”ChEMBL 37, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07174310Parkinson Disease · United States, Australia, Austria and more3RecruitingHoffmann-La RocheJun 30, 2029900
NCT04777331Parkinson Disease · United States, Austria, Canada and more2Active, not recruitingHoffmann-La RocheSep 11, 2024586
NCT03100149Parkinson Disease · United States, Austria, France and more2Active, not recruitingHoffmann-La RocheNov 27, 2019316
NCT02157714Parkinson Disease · United States1CompletedProthena BiosciencesSep 201664
NCT02095171Parkinson Disease · United States1CompletedProthena BiosciencesDec 201440

How it is read

Names in the registry

  • “Prasinezumab”, 2 entries
  • “RO7046015”, 2 entries
  • “PRX002”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.